about
Comparison of delivery strategies for pharmacogenetic testing servicesBarriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panelPilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommendedToward clinical genomics in everyday medicine: perspectives and recommendationsClinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Pharmacogenetic testing: Current Evidence of Clinical Utility.Documenting Pharmacogenomic Testing with CPT Codes.Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge.Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.The potential impact of pharmacogenetic testing on medication adherencePayer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.Psychiatric Pharmacogenomics: How Close Are We?Genomic medicine: a decade of successes, challenges, and opportunities.Stakeholder views on pharmacogenomic testing.Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Clinical application of pharmacogenetics: focusing on practical issues.Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.Collaborative Counseling Considerations for Pharmacogenomic Tests.CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic.Payer coverage policies for multigene tests.The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to ImplementationBarriers to clinical adoption of next-generation sequencing: a policy Delphi panel's solutions.Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology.EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.The challenges of implementing pharmacogenomic testing in the clinic.When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children.Medicare and Amyloid PET Imaging: The Battle Over Evidence.Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
P2860
Q26860925-F3707F15-D0C8-4AE6-BFBC-725E8B4E1F87Q28595689-481105A5-B77D-442F-A6CA-2C015A4A7233Q30612258-BDEDE620-2A68-4709-8594-454986ACB9B7Q34990721-8A8867B6-AD01-4123-BE48-2725BC8C34BDQ36825747-AD5D249D-D02F-4019-BC2D-64B2AA5C150EQ37065155-11E07300-2AC9-4D65-A9B1-B2DED471B0A4Q37151528-04526278-1BA4-4AA3-82A2-EE2F27510B95Q37206511-49A611C5-5E09-4005-B0A9-CC35EA93384EQ37241404-BBB6E54E-37B9-4A4F-9879-54DDA410C758Q37262198-9015FE2A-76B9-4E0E-8944-B41740E2CB21Q37612442-750D6FB3-5426-47A0-9838-9416872EDA5BQ37671210-59B23C17-90CA-4779-AE58-C142530FEC60Q37716310-29B61149-E2C2-4D94-B74E-7E35AB026A39Q37727674-7A1763F5-5E7F-4813-A88A-8DEE7799CD17Q38114005-BB07BDB8-7694-4A3E-9223-58CD1648E56AQ38156135-0FEAF61B-C939-4EB3-A022-F3216406FDE1Q38510741-C638C76D-A8B0-485D-BC0D-3D395A99924AQ38593942-C719BF69-EB2A-42A0-A465-5488C5E7BE98Q39052622-AB066154-DF8A-4C0C-A67D-8CB25863BCE2Q39411218-04C1D0F0-31E3-4A90-BCCB-2BC1482E27DCQ41197664-F404847F-2E41-4D2A-BBC2-FA00B335E425Q41364132-73648EE2-0ED3-436E-948D-BE9D4C828DE0Q41433207-8063B42D-3741-4622-92C8-CE390BCEA6AEQ45951369-502AE183-1C54-48F8-86B8-B4BB6C047F2FQ46062336-FCF8EEDA-540F-4EB7-8318-D368CF15C785Q46486965-A0DB3FAC-EBFF-42C0-83D6-98FA24A6FEBEQ47277604-D34446E6-6242-4686-A7B1-32CED9688085Q47929031-51202755-8353-4857-BDB2-AC2176D84B28Q52349592-2C962005-F97D-4D9C-A75C-DB70A35DCD99Q52982412-2C9D8394-BEB9-4FDC-8AF4-D814FD35B6D1Q55407214-225F30B2-6EAF-4BE8-A2E1-E9FC1FD0BF06Q55458851-FFC52813-0A11-4986-A72B-C08ACFD608FB
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Insurance coverage policies for personalized medicine.
@ast
Insurance coverage policies for personalized medicine.
@en
Insurance coverage policies for personalized medicine.
@nl
type
label
Insurance coverage policies for personalized medicine.
@ast
Insurance coverage policies for personalized medicine.
@en
Insurance coverage policies for personalized medicine.
@nl
prefLabel
Insurance coverage policies for personalized medicine.
@ast
Insurance coverage policies for personalized medicine.
@en
Insurance coverage policies for personalized medicine.
@nl
P2860
P356
P1476
Insurance coverage policies for personalized medicine.
@en
P2093
Susanne B Haga
P2860
P304
P356
10.3390/JPM2040201
P577
2012-10-30T00:00:00Z